SLATE-ASSET-MANAGEMENT
23.11.2021 09:02:36 CET | Business Wire | Press release
Slate Asset Management ("Slate" or “the firm”), a global alternative investment platform focused on real estate, today announced that it has appointed Bozena Jankowska as Managing Director and Global Head of Environmental, Social and Governance (“ESG”), based in Slate’s London office.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005469/en/
Jankowska has nearly two decades of experience at the intersection of finance and corporate responsibility. She will lead the development of best-in-class ESG practices and policies aimed at safeguarding the long-term performance of Slate’s global investments. Additionally, Jankowska will oversee and advance Slate’s corporate social responsibility strategy and the integration of ESG into Slate’s investment and asset management processes, as well as stakeholder communications and reporting. Her focus over the next year will be to complete an ESG assessment of Slate’s assets under management, with an initial focus on Europe, before subsequently expanding to the entirety of Slate’s global platform.
“We are very pleased to welcome Bozena to our team,” said Brady Welch, Founding Partner at Slate. “From the outset, Bozena’s commitment to innovation and her entrepreneurial spirit set her apart from other candidates. She led the drive for sustainability in the finance industry well before it became mainstream, and her deep-rooted technical knowledge of complex global sustainability topics will be extremely valuable as we continue driving our ESG strategy forward.”
Blair Welch, Founding Partner at Slate Asset Management, added: “We understand that having sound ESG practices underpinning our approach to investment and asset management benefits our tenants, our communities and our investors. Bozena’s appointment displays our deep commitment to embedding ESG principles across our business.”
Jankowska was Global Co-Head of ESG at Allianz Global Investors (“AGI”), responsible for ESG integration across the firm’s investment portfolio. During her 15-year tenure at AGI, she pioneered a number of innovative ESG strategies and processes, establishing a global ESG team and growing AGI’s total sustainable investment assets under management from €70 million to over €30 billion. She also designed, managed and marketed the Allianz Global Investors clean technology fund – Global Ecotrends – which grew from $10 million in seed funding to $1 billion in assets under management, becoming a global franchise for the firm.
After leaving AGI, Jankowska founded a successful women’s sustainable fashion label, overseeing the brand’s business strategy and creative direction, including sustainable materials research and sourcing, supply chain management, and successful partnerships with non-governmental organizations focused on environmental sustainability.
“I am excited to join an organization that clearly understands how best-in-class ESG practices can play a critical role in long-term value creation,” said Jankowska. “I look forward to working with the team at Slate to continue raising the bar on the firm’s ESG performance and identifying new and innovative ways to add further rigor to our ESG approach.”
Jankowska holds a Bachelor of Science in Environmental Science from the University of Sussex. She completed her Master of Science in Environment Technology with distinction at Imperial College.
Jankowska joined Slate on November 22.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform focused on real estate. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com
to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005469/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
